Patents Assigned to Aska Pharmaceutical Co., Ltd.
-
Publication number: 20240083867Abstract: A compound of the formula (I) or a salt thereof (R represents methyl group or fluorine atom) having an mPGES-1 inhibitory activity and useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of such diseases as inflammation, pain, or rheumatism.Type: ApplicationFiled: February 1, 2022Publication date: March 14, 2024Applicant: ASKA PHARMACEUTICAL CO., LTD.Inventors: Makoto OKADA, Youichi NAKANO, Takashi NOSE, Satoshi MAEDA, Tomoaki WATANABE
-
Publication number: 20240041899Abstract: Provided is a solid preparation having an excellent stability and being useful for treating or improving (or alleviating) a urination disorder regardless of the degree or presence of prostatomegaly. The solid preparation contains a 2-oxapregnane compound represented by the following formula (1) as an active ingredient, and a carrier. In the formula, R1 to R3 each represent an alkyl group such as a methyl group, R4 represents an alkylcarbonyl group such as an acetyl group, X represents a halogen atom such as a chlorine atom, and Y represents a hydroxyl group or oxo group bonded to the 11-position, 15-position, or 16-position of the steroid skeleton. The carrier contains a first carrier and/or a second carrier; the first carrier is not a metal salt-form, and the second carrier is a polyvalent metal salt-form of an inorganic acid.Type: ApplicationFiled: December 17, 2021Publication date: February 8, 2024Applicant: ASKA Pharmaceutical Co., Ltd.Inventors: Sakiko KITAMURA, Kazuhiro SASAKI, Hiroshige KATAOKA, Asuka OZAWA, Hideo KOBAYASHI, Atsushi SHINBO, Youichi NAKANO, Yuta ITO, Junichi WATANABE
-
Publication number: 20230301909Abstract: The present invention addresses the problem of providing a pregnancy-induced hypertension syndrome therapy composition having controlled placental permeability. Provided are nicotinamide-encapsulating micelles having a particle diameter of 25-100 nm. Controlling the particle diameter of the nicotinamide-encapsulating micelles enables control of placental permeability so as to make it possible to accumulate nicotinamide-encapsulating micelles in a placental while suppressing transfer to a fetus. Administering the nicotinamide-encapsulating micelles brings about a superior effect of reducing blood pressure during a pregnancy-induced hypertension syndrome.Type: ApplicationFiled: October 8, 2021Publication date: September 28, 2023Applicants: The University of Tokyo, ASKA Pharmaceutical Co., Ltd.Inventors: Horacio Cabral, Takuya Miyazaki, Pengwen Chen, Naoya Kawashima
-
Patent number: 11752102Abstract: A powder preparation for nasal administration containing a particulate of steroid hormones having an average particle size of 50 to 300 ?m as an active ingredient is prepared.Type: GrantFiled: December 20, 2021Date of Patent: September 12, 2023Assignee: ASKA PHARMACEUTICAL CO., LTD.Inventors: Koichi Minato, Tomoya Fujisawa, Kenji Shimizu, Takahisa Saito, Hiroya Yajima, Kazuhiro Sasaki
-
Publication number: 20230168257Abstract: Described is a method for differentiating destructive thyroiditis, including measuring at least one of monoiodotyrosine and diiodotyrosine in a sample.Type: ApplicationFiled: March 31, 2021Publication date: June 1, 2023Applicant: ASKA PHARMACEUTICAL CO., LTD.Inventors: Yuji TANAKA, Yosuke ONO, Naoya FUJITA
-
Publication number: 20220331340Abstract: Provided is a urination disorder-improving agent useful for treating or improving (or alleviating) a urination disorder regardless of the degree or presence of prostatomegaly. The urination disorder-improving agent contains a 2-oxapregnane compound represented by the following formula (1) as an active ingredient. (In the formula, R1 to R3 represent an alkyl group such as methyl group, R4 represents an alkylcarbonyl group such as acetyl group, X represents a halogen atom such as a chlorine atom, Y represents a hydroxyl group or oxo group bonded to the 11-position, 15-position, or 16-position of the steroid skeleton.Type: ApplicationFiled: January 29, 2020Publication date: October 20, 2022Applicant: ASKA Pharmaceutical Co., Ltd.Inventors: Hideo KOBAYASHI, Atsushi SHINBO, Youichi NAKANO, Yuta ITO, Junichi WATANABE
-
Publication number: 20220125716Abstract: A powder preparation for nasal administration containing a particulate of steroid hormones having an average particle size of 50 to 300 ?m as an active ingredient is prepared.Type: ApplicationFiled: December 20, 2021Publication date: April 28, 2022Applicant: ASKA Pharmaceutical Co., Ltd.Inventors: Koichi MINATO, Tomoya FUJISAWA, Kenji SHIMIZU, Takahisa SAITO, Hiroya YAJIMA, Kazuhiro SASAKI
-
Patent number: 11234928Abstract: A powder preparation for nasal administration containing a particulate of steroid hormones having an average particle size of 50 to 300 ?m as an active ingredient is prepared.Type: GrantFiled: November 22, 2018Date of Patent: February 1, 2022Assignee: ASKA PHARMACEUTICAL CO., LTD.Inventors: Koichi Minato, Tomoya Fujisawa, Kenji Shimizu, Takahisa Saito, Hiroya Yajima, Kazuhiro Sasaki
-
Publication number: 20200360274Abstract: A powder preparation for nasal administration containing a particulate of steroid hormones having an average particle size of 50 to 300 ?m as an active ingredient is prepared.Type: ApplicationFiled: November 22, 2018Publication date: November 19, 2020Applicant: ASKA Pharmaceutical Co., Ltd.Inventors: Koichi MINATO, Tomoya FUJISAWA, Kenji SHIMIZU, Takahisa SAITO, Hiroya YAJIMA, Kazuhiro SASAKI
-
Patent number: 10815268Abstract: Provided is a process for producing a compound, which has an oxo group specifically introduced on the 15-position of a steroid skeleton and which is useful as an intermediate, with a high yield without complicated steps. A compound represented by the formula (2) is allowed to react with an oxidant (e.g., a hypervalent iodine compound) and a co-oxidant (e.g., a peroxide) to produce a 15-oxosteroid compound represented by the formula (1), which is useful as an intermediate: wherein R1 to R3 are the same or different and each represent a halogen atom, an alkyl group, a haloalkyl group, an alkoxy group, or a haloalkoxy group, R4 represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an acyl group, or an alkoxycarbonyl group, R5 represents a hydrogen atom, an alkyl group, or an acyl group, R6 represents a hydrogen atom, an alkyl group, an acyl group, or a sulfonyl group, X represents an oxygen atom (O) or a methylene group (CH2).Type: GrantFiled: February 8, 2018Date of Patent: October 27, 2020Assignee: ASKA PHARMACEUTICAL CO., LTD.Inventors: Yosuke Takenaka, Norihito Isomura, Akira Asagarasu, Hiroshi Uchida
-
Publication number: 20200283469Abstract: Provided are a novel internal standard useful in the measurement of androgens, a method capable of measuring the androgen in a highly selective and highly sensitive (accurate) manner using liquid chromatography mass spectrometry with simplified pretreatments, and a method for diagnosis of a disease using the androgen measurement method. The novel stable isotope-labeled compound is synthesized by performing reduction reaction in a specific solvent. An androgen is measured using this novel stable isotope-labeled compound as an IS.Type: ApplicationFiled: November 13, 2018Publication date: September 10, 2020Applicant: ASKA PHARMACEUTICAL CO., LTD.Inventors: Koichi MINATO, Yusuke ITO
-
Patent number: 10710967Abstract: A compound represented by the formula (1), or a salt thereof (X represents carbonyl group, or sulfonyl group; R1 represents hydrogen atom, a halogen atom, an alkyl group, an alkanoyl group, cyano group, or carboxyl group; R2 represents an alkyl group, a cyclic carbon group, or a heterocyclic group; R3 represents hydrogen atom, or 1 to 3 substituents; R4 and R5 represents hydrogen atom, a halogen atom, or an alkyl group; and R6 represents an alkyl group, or an alkoxy group), which has an mPGES-1 inhibitory action, and is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of inflammation, pain, rheumatism, and the like.Type: GrantFiled: October 28, 2016Date of Patent: July 14, 2020Assignee: ASKA PHARMACEUTICAL CO., LTD.Inventors: Makoto Okada, Youichi Nakano, Takashi Nose, Takahiro Nishimoto, Satoshi Maeda
-
Patent number: 10640749Abstract: Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.Type: GrantFiled: May 28, 2015Date of Patent: May 5, 2020Assignees: NC MEDICAL RESEARCH INC., ASKA PHARMACEUTICAL CO., LTD., MITSUI SUMITOMO INSURANCE CARE NETWORK CO., LTD.Inventors: Osamu Honmou, Kazuo Hashi, Teiji Uede
-
Patent number: 10632065Abstract: The present invention provides a microneedle device comprising: a substrate; a microneedle disposed on the substrate; and a coating layer formed on the microneedle; in which the coating layer comprises a recombinant follicle-stimulating hormone, arginine, and glycerin, in the coating layer, the mass of arginine is 0.07 to 0.75-fold of the mass of the recombinant follicle-stimulating hormone and the mass of glycerin is 0.1 to 2.75-fold of the mass of the recombinant follicle-stimulating hormone.Type: GrantFiled: October 19, 2015Date of Patent: April 28, 2020Assignees: HISAMITSU PHARMACEUTICAL CO., INC., ASKA PHARMACEUTICAL CO., LTD.Inventors: Shinpei Nishimura, Seiji Tokumoto, Takeshi Ito, Hajime Asada
-
Publication number: 20200071280Abstract: A compound represented by the formula (1), or a salt thereof (X represents carbonyl group, or sulfonyl group; R1 represents hydrogen atom, a halogen atom, an alkyl group, an alkanoyl group, cyano group, or carboxyl group; R2 represents an alkyl group, a cyclic carbon group, or a heterocyclic group; R3 represents hydrogen atom, or 1 to 3 substituents; R4 and R5 represents hydrogen atom, a halogen atom, or an alkyl group; and R6 represents an alkyl group, or an alkoxy group), which has an mPGES-1 inhibitory action, and is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of inflammation, pain, rheumatism, and the like.Type: ApplicationFiled: October 28, 2016Publication date: March 5, 2020Applicant: ASKA PHARMACEUTICAL CO., LTD.Inventors: Makoto OKADA, Youichi NAKANO, Takashi NOSE, Takahiro NISHIMOTO, Satoshi MAEDA
-
Publication number: 20190389900Abstract: Provided is a process for producing a compound, which has an oxo group specifically introduced on the 15-position of a steroid skeleton and which is useful as an intermediate, with a high yield without complicated steps. A compound represented by the formula (2) is allowed to react with an oxidant (e.g., a hypervalent iodine compound) and a co-oxidant (e.g., a peroxide) to produce a 15-oxosteroid compound represented by the formula (1), which is useful as an intermediate: wherein R1 to R3 are the same or different and each represent a halogen atom, an alkyl group, a haloalkyl group, an alkoxy group, or a haloalkoxy group, R4 represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an acyl group, or an alkoxycarbonyl group, R5 represents a hydrogen atom, an alkyl group, or an acyl group, R6 represents a hydrogen atom, an alkyl group, an acyl group, or a sulfonyl group, X represents an oxygen atom (O) or a methylene group (CH2).Type: ApplicationFiled: February 8, 2018Publication date: December 26, 2019Applicant: ASKA Pharmaceutical Co., Ltd.Inventors: Yosuke TAKENAKA, Norihito ISOMURA, Akira ASAGARASU, Hiroshi UCHIDA
-
Patent number: 10508130Abstract: Provided is a crystalline polymorphic form A of 15?-hydroxy-osaterone acetate having an improved stability (storage stability, pulverization stability, and absorption characteristics). In a powder X-ray diffraction spectrum, characteristic diffraction peaks of the crystalline polymorphic form A of 15?-hydroxy-osaterone acetate appear at diffraction angles 2? of 9.6°±0.2°, 17.1°±0.2°, and 20.2°±0.2°. The crystalline polymorphic form A has a melting point of 280 to 283° C. and is a prism crystal.Type: GrantFiled: May 10, 2017Date of Patent: December 17, 2019Assignee: ASKA PHARMACEUTICAL CO., LTD.Inventors: Takayoshi Nakagawa, Hiroyuki Hayashi, Koichi Miyazaki, Shigeki Iwashita
-
Publication number: 20190127417Abstract: Provided is a crystalline polymorphic form A of 15?-hydroxy-osaterone acetate having an improved stability (storage stability, pulverization stability, and absorption characteristics). In a powder X-ray diffraction spectrum, characteristic diffraction peaks of the crystalline polymorphic form A of 15?-hydroxy-osaterone acetate appear at diffraction angles 2? of 9.6°±0.2°, 17.1°±0.2°, and 20.2°±0.2°. The crystalline polymorphic form A has a melting point of 280 to 283° C. and is a prism crystal.Type: ApplicationFiled: May 10, 2017Publication date: May 2, 2019Applicant: ASKA Pharmaceutical Co., Ltd.Inventors: Takayoshi NAKAGAWA, Hiroyuki HAYASHI, Koichi MIYAZAKI, Shigeki IWASHITA
-
Patent number: 9643994Abstract: A novel crystalline polymorphic form of ulipristal acetate useful as an agent for preventing and/or treating uterine leiomyoma and as a contraceptive, and a process for producing the crystalline polymorphic form are provided. The novel crystalline polymorphic form of ulipristal acetate is obtained by crystallization or transition in association with a specified solvent. The solvent comprises at least one member selected from the group consisting of water, an aliphatic hydrocarbon, an aromatic hydrocarbon, a halogenated hydrocarbon, a linear alcohol, an alkyl ether, an acetate ester, an alkyl ketone, an N-alkylacylamide, and an alkanenitrile.Type: GrantFiled: September 26, 2013Date of Patent: May 9, 2017Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Shigeki Iwashita, Hiroyuki Hayashi, Koichi Miyazaki
-
Patent number: 9643993Abstract: A novel crystalline polymorphic form of ulipristal acetate useful as an agent for preventing and/or treating uterine leiomyoma and as a contraceptive, and a process for producing the crystalline polymorphic form are provided. The novel crystalline polymorphic form of ulipristal acetate is obtained by dissolving an isopropanol-solvated crystal of ulipristal acetate in a mixed solvent containing ethanol and water, and crystallizing an ulipristal acetate from the solution without addition of a seed crystal to the solution.Type: GrantFiled: September 26, 2013Date of Patent: May 9, 2017Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Shigeki Iwashita, Hiroyuki Hayashi, Koichi Miyazaki